 Analysts at Noble Capital have reiterated an Outperform rating and 5 price target on Genprex Inc which recently announced that the first cohort from its Phase 12 Acclaim-1 trial in non-small cell lung cancer NSCLC has shown sufficient safety to allow treatment of a second cohort at a higher dose. The approval came from the Safety Review Committee SRC after it analyzed patient data in the first cohort. 